Drugs / LVIVO-TaVec400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07583030 | Apr 2026 → Sep 2028 expected | immunoglobulin G4-related sclerosing disease, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07399444 | Jan 2026 → Jul 2028 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVIVO-TaVec400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07399444 ↗ |
| Modality | Cell therapy | “LVIVO-TaVec400, an in vivo chimeric antigen receptor (CAR) -T cell therapy” NCT07583030 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT07583030 ↗ |